» LEARN MORE ABOUT COVID-19 VACCINES, TESTING, VISITOR & SAFETY REQUIREMENTS

MyHealth

Manage your account, request prescriptions, set up appointments & more.

LOG IN
Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label

JIA Registry - Abatacept

Trial

Clinical Trial Title

Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

Trial Status

Open to Enrollment

Start Date

March 15, 2013

Trial Type

Pediatric Rheumatology

Specific Condition

Juvenile Idiopathic Arthritis (JIA)

Description

The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) in routine clinical practice, with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.

Eligibility Criteria

Ages Eligible for Study:  up to 17

Genders Eligible for Study:  Both

Inclusion Criteria:

  • Diagnosis of JIA (any subtype).
  • Age < 18 years at the time of enrollment.
  • Receiving Abatacept at the time of enrollment as per treating physician's decision.
  • Parent or legally acceptable representative willing to participate in the study and sign the informed consent.

IRB Number

10608

Principal Investigator Name

Daniel Kingsbury, MD

Contact Name

Karla Kummer

Phone

503-413-1612

Contact E-Mail

kkummer@lhs.org

Last Updated: Wednesday, January 27, 2021 12:07:38 PM